Duchuangsanzhong Biotech

Duchuangsanzhong Biotech is a Chinese biopharmaceutical company focused on the discovery and development of next-generation precision oncology therapies, specifically targeting synthetic lethality pathways. The company's primary research focus is on DNA damage response (DDR) mechanisms, with a lead program targeting DNA polymerase theta (POLQ) for the treatment of HR-deficient cancers. By leveraging its proprietary drug discovery platform, Duchuangsanzhong aims to develop highly selective small molecule inhibitors that can overcome resistance to existing PARP inhibitors. The company is headquartered in Beijing and operates within the burgeoning domestic biotech ecosystem focused on innovative cancer treatments.